Sprycel Market Report 2026

The sprycel market size has grown steadily in recent years. It will grow from $2.15 billion in 2025 to $2.24 billion in 2026 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to high leukemia incidence, resistance to first-line therapies, clinical success of tyrosine kinase inhibitors, hospital oncology adoption, regulatory approvals.

The sprycel market size is expected to see steady growth in the next few years. It will grow to $2.65 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to growth in precision oncology, personalized cancer treatment, expansion of specialty care, oncology drug innovation, improved survival rates. Major trends in the forecast period include continued use of targeted leukemia therapies, rising use in drug-resistant cml, expansion of precision oncology treatments, growth of specialty oncology pharmacies, focus on long-term disease management.

The rising prevalence of leukemia is expected to drive growth in the Sprycel market in the coming years. Leukemia is a blood and bone marrow cancer characterized by the excessive production of abnormal white blood cells. Its increasing prevalence is largely linked to an aging population, as older individuals are more susceptible to the disease, leading to higher diagnosis rates. Sprycel (dasatinib) is effective in treating certain types of leukemia, including Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), by inhibiting the BCR-ABL protein responsible for cancer cell proliferation. For example, according to the American Cancer Society (ACS), approximately 59,610 people were diagnosed with leukemia in 2023 in the United States, with around 23,940 deaths. This rising incidence of leukemia is a key factor supporting the expansion of the Sprycel market.

Increasing healthcare expenditure is also expected to propel the Sprycel market. Healthcare expenditure refers to the total spending on medical services and products within a region or country over a specific period. Rising costs are driven by advancements in medical technology, which introduce expensive diagnostic tools and treatments that improve patient outcomes but elevate overall expenses. Higher healthcare spending enables broader access to innovative cancer therapies like Sprycel, allowing hospitals and healthcare systems to invest in advanced oncology treatments. For instance, in April 2025, the UK Office for National Statistics reported a 6.5% nominal increase in total healthcare spending from 2023 to 2024, slightly up from the 6.3% growth observed in 2023. This trend is contributing to the growth of the Sprycel market.

Major companies in the Sprycel market are focusing on developing generic versions of the drug to capitalize on the impending loss of exclusivity and meet growing demand for affordable cancer treatments. Generic Sprycel refers to dasatinib-based medications produced by other companies after the original patent expires, offering the same therapeutic benefits at lower costs. For example, in September 2024, Apotex Corp., a Canada-based pharmaceutical company, launched dasatinib tablets, a generic form of Sprycel. Dasatinib is a kinase inhibitor used to treat certain types of leukemia in adults and children aged one year and older, including Philadelphia chromosome-positive CML and ALL, particularly in cases where previous treatments were ineffective or not tolerated. The product is designed to meet high-quality standards - being latex-free, sugar-free, dye-free, alcohol-free, and preservative-free - and is available in bottles of 30 or 60 tablets depending on strength.

Major companies operating in the sprycel market are Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co. Ltd., Beacon Pharmaceuticals Limited, Panacea Biotec Limited, Apotex Corp., Hubei Haosun Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, Zydus Lifesciences Limited, Biocon Limited, Zentiva k.s., Alembic Pharmaceuticals Limited, Granules India Limited, Natco Pharma Limited, Shilpa Medicare Limited, Prasco Laboratories, Stason Pharmaceuticals Inc., HRV Global Life Sciences Pvt. Ltd., Sichuan Elixir Pharmaceutical Co. Ltd., Gonane Pharma Limited.

Asia-Pacific was the largest region in the sprycel market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the sprycel market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sprycel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the sprycel market by increasing the cost of imported active pharmaceutical ingredients and oncology intermediates used in targeted cancer therapy manufacturing. These impacts are most pronounced in North America and Europe, where reliance on global oncology supply chains is high. Rising tariff related expenses have contributed to higher treatment costs and budget pressure for healthcare providers. This has influenced procurement planning and pricing negotiations in oncology care settings. However, tariffs have encouraged domestic oncology drug manufacturing, expanded local production capacity, and improved long term supply chain resilience.

The sprycel market research report is one of a series of new reports that provides sprycel market statistics, including sprycel industry global market size, regional shares, competitors with a sprycel market share, detailed sprycel market segments, market trends and opportunities, and any further data you may need to thrive in the sprycel industry. This sprycel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sprycel is a prescription medication used primarily to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) by targeting specific proteins involved in cancer cell growth. It helps prevent the uncontrolled proliferation of leukemia cells, providing a targeted treatment option for patients who are resistant or intolerant to other therapies.

The main indications for Sprycel are chronic myeloid leukemia and acute lymphoblastic leukemia. Chronic myeloid leukemia (CML) is a slow-progressing cancer of the bone marrow and blood caused by a genetic mutation known as the Philadelphia chromosome. Sprycel is available in various dosage forms, including tablets and oral suspension, and is distributed through hospitals and clinics, retail pharmacies, online pharmacies, and specialty pharmacies.

The sprycel market consists of sales of products including film-coated tablets, powder for oral suspension, blister packaging, pediatric dosing packs, and flavoring agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.